| Literature DB >> 35078528 |
Vinogrin Dorsamy1, Chauntelle Bagwandeen2, Jagidesa Moodley3.
Abstract
BackgroundAnaemia is associated with maternal and perinatal morbidity and mortality. The pooled prevalence of anaemia in the South African (SA) pregnant population was ascertained by systematically reviewing available literature. Severity, risk factors (HIV, tuberculosis, race, province, year of study), maternal morbidity and mortality (hypertensive disorders of pregnancy), birth outcomes (including low birth weight) and supplementation during pregnancy were also described.MethodsEligible studies reported on haemoglobin concentration or prevalence of anaemia in a SA pregnant population and were available in full text. Case-control and estimation studies were excluded with no restriction on the date of publication. PubMed, CINAHL, EMBASE, EBSCO, Ovid maternity and infant care databases, Cochrane Database of Systematic Reviews, Web of Science and SCOPUS were searched, using the keywords 'anaemia', 'haemoglobin', 'pregnancy', 'South Africa'. Risk of bias was conducted using the Hoy tool and the Doi plot and LFK ratio. Overall study quality was assessed using the GRADE tool. Due to heterogeneity amongst studies subgroup analyses were performed (random effects and quality effects model) using MetaXL addon tool for Microsoft Excel.ResultsThe initial search yielded 7010 articles and 26 were selected for inclusion. Twenty studies were cross-sectional, three were longitudinal and one a randomised control trial. Studies ranged in publication year from 1969 to 2020. The pooled prevalence of anaemia in pregnant women in SA was determined to be 31% (95% CI, 23-40%). Hypertensive disorders of pregnancy and low birth weight were associated with anaemia. While iron deficiency was reported as the main cause, other risk factors included HIV and other infections.DiscussionLimitationsThere was limited data reporting on prevalence of anaemia and direct maternal and foetal outcomes. Heterogeneity amongst studies was not explained by subgroup analysis. Majority of cross-sectional study designs reduced the ability to infer causality.InterpretationWhile the prevalence of anaemia remains high and of concern, risk factors are varied. Iron deficiency is still common but the presence of comorbidities also contributes to anaemia and should not be ignored. More longitudinal research into associations between anaemia and birth outcomes is needed due to a lack of available evidence.Systematic review registrationPROSPERO 2020: CRD42020157191.Entities:
Keywords: Anaemia; Haemoglobin; Maternal; Pregnant; South Africa
Mesh:
Year: 2022 PMID: 35078528 PMCID: PMC8789334 DOI: 10.1186/s13643-022-01884-w
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Fig. 1PRISMA flow diagram of the present review. Adopted from PRISMA 2020 statement [17]
Fig. 2Forest plot listing proportions and the overall pooled proportion as well as I2 and Cochrane’s Q indicative of complete heterogeneity of studies
Summary and sensitivity analysis of prevalence across selected studies with column values of prevalence and low (LCI) and high (HCI) confidence intervals showing proportions. The value of the pooled prevalence change is depicted in the second column (‘Pooled prevalence proportion’) if the study to the left (‘Included study’) is removed from the calculation
| Included study | Pooled prevalence proportion | LCI 95% | HCI 95% | Cochrane’s | ||||
|---|---|---|---|---|---|---|---|---|
| Akinsooto 2020 [ | 0.33 | 0.26 | 0.40 | 1526.19 | 0.00 | 98.43 | 98.14 | 98.67 |
| Becker 1970 [ | 0.34 | 0.26 | 0.41 | 1507.74 | 0.00 | 98.41 | 98.12 | 98.66 |
| Bloch 2020 [ | 0.33 | 0.26 | 0.41 | 1533.65 | 0.00 | 98.44 | 98.15 | 98.68 |
| Bopape 2008 [ | 0.33 | 0.26 | 0.40 | 1538.45 | 0.00 | 98.44 | 98.16 | 98.68 |
| Donald 2019 [ | 0.33 | 0.26 | 0.41 | 1521.18 | 0.00 | 98.42 | 98.13 | 98.67 |
| Govender 2018 [ | 0.33 | 0.26 | 0.41 | 1538.07 | 0.00 | 98.44 | 98.15 | 98.68 |
| Hoque 2007 [ | 0.31 | 0.24 | 0.38 | 1284.27 | 0.00 | 98.13 | 97.77 | 98.44 |
| Kerkhoff 2014 [ | 0.33 | 0.26 | 0.40 | 1528.12 | 0.00 | 98.43 | 98.14 | 98.67 |
| Kesho Bora 2013 [ | 0.32 | 0.25 | 0.40 | 1471.21 | 0.00 | 98.37 | 98.07 | 98.62 |
| Lamparelli 1988 [ | 0.34 | 0.27 | 0.41 | 1471.28 | 0.00 | 98.37 | 98.07 | 98.62 |
| Lamparelli 1988b [ | 0.34 | 0.26 | 0.41 | 1495.27 | 0.00 | 98.39 | 98.10 | 98.64 |
| Levy 2018 [ | 0.33 | 0.26 | 0.40 | 1527.69 | 0.00 | 98.43 | 98.14 | 98.67 |
| Macaulay 2018 [ | 0.34 | 0.26 | 0.42 | 1505.33 | 0.00 | 98.41 | 98.11 | 98.65 |
| Mathee 2014 [ | 0.33 | 0.26 | 0.41 | 1490.16 | 0.00 | 98.39 | 98.09 | 98.64 |
| Mayet 1985 [ | 0.33 | 0.26 | 0.41 | 1492.08 | 0.00 | 98.39 | 98.09 | 98.64 |
| Mkhize 2019 [ | 0.33 | 0.26 | 0.40 | 1529.13 | 0.00 | 98.43 | 98.14 | 98.67 |
| Nandlal 2014 [ | 0.33 | 0.26 | 0.40 | 1380.84 | 0.00 | 98.26 | 97.93 | 98.54 |
| Notelovitz 1972 [ | 0.33 | 0.26 | 0.41 | 1508.80 | 0.00 | 98.41 | 98.12 | 98.66 |
| Ross 1981 [ | 0.33 | 0.25 | 0.41 | 1537.91 | 0.00 | 98.44 | 98.15 | 98.68 |
| Symington 2019 [ | 0.33 | 0.26 | 0.41 | 1535.92 | 0.00 | 98.44 | 98.15 | 98.68 |
| Tunkyi 2015 [ | 0.32 | 0.25 | 0.40 | 1464.87 | 0.00 | 98.36 | 98.06 | 98.62 |
| Tunkyi 2017 [ | 0.32 | 0.25 | 0.40 | 1464.87 | 0.00 | 98.36 | 98.06 | 98.62 |
| Tunkyi 2018 [ | 0.32 | 0.25 | 0.40 | 1464.87 | 0.00 | 98.36 | 98.06 | 98.62 |
| van Bogaert 2006 [ | 0.35 | 0.28 | 0.42 | 1122.85 | 0.00 | 97.86 | 97.43 | 98.23 |
| Weyers 2016 [ | 0.33 | 0.26 | 0.40 | 1538.68 | 0.00 | 98.44 | 98.16 | 98.68 |
| Wilkinson 1997 [ | 0.33 | 0.27 | 0.41 | 1349.66 | 0.00 | 98.22 | 97.88 | 98.51 |
Fig. 3a-c Forest plots showing pooled prevalence according to the severity of anaemia grouped into a mild (Hb 9.0–11.0 g/dL), b moderate (Hb 7.0–8.9 g/dL) and c severe (Hb < 7.0 g/dL)
Fig. 4Subgroup analysis by year of study with 3 groups: pre-1994, post-1994 (abolishment of apartheid) and post-2002 (PMTCT was introduced)
Fig. 5Subgroup analysis by race with 4 subgroups. Where race was not specified within studies, all races were assumed to be included within that study
Fig. 6Subgroup analysis by study quality separated into low quality (1–3), moderate (4–6) and high quality (7–9) according to the Hoy tool [21] used to assess study quality
Fig. 7Subgroup analysis by whether studies reported on HIV as an outcome or co-factor in anaemia
Fig. 8Subgroup analysis by whether studies reported on birth weight as an outcome or co-factor in anaemia
Maternal anaemia and birth outcomes
| Author, year | Description of birth outcomes |
|---|---|
| Donald 2019 [ | Decrease in cognitive development in children, especially boys in presence of maternal anaemia. |
| Govender 2018 [ | LBW and low Apgar scores reported associated with late booking of ANC. No association determined for anaemia and birth outcome parameters. |
| Mkhize 2019 [ | LBW associated with the 34-week group only. |
| Nandlal 2014 [ | No difference in birth weight between groups. Infants born to mothers who presented with anaemia in pregnancy were twice more likely to be anaemic. |
| Nojilana 2007 [ | IDA associated with 37% perinatal mortality and mild mental disability. |
| Symington 2019 [ | Inverse relationship between birthweight and maternal anaemia. |
| Tunkyi 2017 [ | Increase in placenta abruptio in patients on ARV’s. |
| Tunkyi 2018 [ | LBW, preterm delivery associated with anaemia. |
| van Bogaert 2006 [ | Anaemia present at early booking may predispose to caesarean section. |
Anaemia associated with hypertensive disorders of pregnancy
| Author, year | Which HDP | Comments HDP | |
|---|---|---|---|
| Macaulay 2018 [ | 505 | Just hypertension per se | Overall prevalence 3.4%, no significant difference between diabetics and non-diabetics |
| Mkhize 2019 [ | 89 | Pre-eclampsia | 4% in > 34 weeks and 4% in < 34 weeks HIV uninfected |
| Nandlal 2014 [ | 262 | Pre-eclampsia | 5.5% in anaemia 5.4% in no anaemia RR 0.98 (0.42–2.28) |
| Tunkyi 2017 [ | 854 | PIH | Significant difference in HIV-infected women on treatment greater than a year |
| Tunkyi 2018 [ | 854 | PIH | Not significant |
Anaemia and supplementation
| Author, year | Supplements | Key findings |
|---|---|---|
| Becker 1970 [ | Iron and folate | No difference observed in untreated subjects, and those treated with iron, and iron and folate |
| Bopape 2008 [ | Iron and folate | No difference in iron, serum ferritin and B12 while folate higher in supplemented groups |
| Dommisse 1969 [ | Oral iron (Gradumet) and injection (Imferon) | Participants responded better to injection than oral in subset of patients with severe anaemia with poor response to folate |
| Kesho Bora 2013 [ | Iron, folate and multivitamins | Routine supplementation presumed to have contributed to rise in HB |
| Lamparelli 1988 [ | Indicated iron and folate supplementation during pregnancy in affluent population | Iron stores still depleted as pregnancy progressed |
| Mkhize 2019 [ | Pregamel for all and ferrous sulphate for anaemia | 20.8% non-adherence overall but adherence was higher in HIV+ group. Improvement noted with adherence to haematinics |
| Ross 1981 [ | Haematinics mentioned in a subgroup for longitudinal study | No difference in dietary supplementation and ferritin levels or Vit C was found between groups |
| Symington 2019 [ | Ferrous sulphate, calcium and folate | 100% compliance and additional supplementation in some |
| Tunkyi 2017 [ | Iron and folate 200 μg | |
| van Bogaert 2006 [ | Haematinics | Only 112 records indicated iron supplementation |